Navigation Links
VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
Date:2/6/2008

Disease Altering Treatment Shows Ability to Prevent HIV from Replicating

GAITHERSBURG, Md., Feb. 6 /PRNewswire/ -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, presented results from its Phase II trial of VRX496, a gene therapy for the treatment of AIDS, at the 2008 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, MA.

"This appears to be a significant demonstration of slowing and possibly halting the replication of the infectious HIV virus in humans," said Dr. Gary Blick, Medical Director, Circle Medical LLC. "VRX496 appears to cause wt-HIV particles to lose their envelopes and the in vivo pressure delivered by a patient's own modified cells leads to massive quasispecie reductions and production of impaired and less replicative virions. This treatment shows tremendous promise."

VRX496 has the potential to change HIV/AIDS care. Currently there are a variety of drugs available for HIV-infected patients, but all have long-term complications. To date, there have been no reported adverse events in any patient receiving VRX496 in clinical trials. In addition, VRX496 does not require daily administration.

"We are proving the effectiveness of our lentiviral vector approach in attacking HIV," said Dr. Laurent Humeau, VP of R&D for VIRxSYS. "Our lentiviral vector VRX496 appears to sustain expression of the RNA antisense targeting the HIV envelope for a long period of time, with a measurable effect on the HIV replicative fitness up to 3 years following a single injection. We believe this will prove to be an important step in the treatment of this disease."

VRX496 is a different viral vector than those used in previous gene therapy trials. VRX496 is derived from HIV-1 itself and has it disease-causing elements removed. Currently, VRX496 is being investigated as a therapeutic treatment (a treatment for those already infected with HIV). Unlike other vir
'/>"/>

SOURCE VIRxSYS Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
4. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. Xenon Announces Appointment of VP, Discovery Research
7. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
8. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
9. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
10. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
11. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015 ... and medical information products and services, today announced the ... According to the 2014 Journal Citation Reports® (JCR) published ... Impact Factors increase from 2013 to 2014, ahead of ... occupied the top rank in 62 subject categories, up ...
(Date:6/26/2015)... ... June 26, 2015 , ... Charm Sciences, Inc. is ... and Stockyards Administration (GIPSA) awarded a five year contract to Charm Sciences to ... Charm’s ROSA DONQ-FAST5 Test. This 5 minute quantitative test extracts DON from samples ...
(Date:6/26/2015)... , June 23, 2015 ... the addition of the "Global Cancer Biosimilars ... Market introduction of cancer biosimilar is ... commercialization potential. Chemotherapeutic drugs have dominated the cancer ... have been introduced in past few years. They ...
(Date:6/25/2015)... 25, 2015 Last June, a dedicated global team ... virus using large-scale genome sequencing. Their research, which was written ... the journal Cell (Park 2015) , reveals ... seven months of the recent Ebola outbreak. Today ... data, workflows, and full edit history of the paper ...
Breaking Biology Technology:Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3Open Science Takes Major Leap Forward 2
... TNGN ), a leader in regenerative medicine, today ... on Wednesday, October 27, 2010 in New York, New York. ... product development portfolio and upcoming corporate milestones, and will expand ... The live webcast of the event will be available ...
... Calif., Oct. 12 With more than 200 ... Workshop, Microsoft Research showcases two technologies that facilitate ... a MODISAzure-based environmental service. (Logo: ... Programmers and developers in bioscience now ...
... The Ontario Institute for Cancer Research (OICR) today announced ... Inc., an Ontario company that is developing a software ... detailed disease and treatment data without compromising individual privacy. ... Assessment Tool (PARAT), is currently being used by hospitals ...
Cached Biology Technology:Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010 2Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 2Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 3Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 4OICR Makes Equity Investment in Medical Information Company 2
(Date:6/18/2015)... June 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market announces that its Wocket® ... on "Money on the Mark", scheduled to air on WABC ... June 20 th . The broadcast air- ... 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... , SANTA ANA, Calif. and ... Microsystems, Inc., d.b.a. Identive Group (Nasdaq: INVE ; Frankfurt ... for the security, identification and RFID industries, today announced that ... three new executives in line with the announced reorganization of ...
... 2010 The Translational Genomics Research Institute (TGen) today ... agreement with the Van Andel Research Institute (VARI) that ... TGen expects the agreement to create a ... and treatments for patient benefit. ...
... Medicine believe they may have discovered how the hormone ... findings will be presented at the Annual Scientific Meeting ... by Errol Norwitz, M.D., professor in the Department of ... Preterm birthdelivery prior to 37 weeks gestationhas become increasingly ...
Cached Biology News:Identive Group Expands Executive Management Team 2Identive Group Expands Executive Management Team 3TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3
...
... Antigen peptide transporter ... TAP2) (Peptide transporter PSF2) ... (PSF-2) (Peptide transporter involved ... [Source:Uniprot/SWISSPROT;Acc:Q03519] ...
... Recognizes Nabeta2. The epitope specific ... in any other known proteins.,SPECIES ... to work on human because ... conserved (17/19 residues). Reactivity with ...
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Biology Products: